Phase II trial of semorinemab in mild-to-moderate Alzheimer's disease (Lauriet): Topline results

Tau pathology, in the form of neurofibrillary tangles, is correlated with disease severity in Alzheimer’s disease (AD). The tau spreading hypothesis postulates that tau spreads from diseased neurons to healthy neurons through the extracellular space; therefore, targeting tau protein has the potential to slow or stop the spread of pathological tau, and consequently slow clinical decline. Semorinemab is an anti-tau antibody that targets all known isoforms of tau and is in clinical development for Alzheimer's disease. This presentation shows the Phase II, multi-center, randomized, double-blind, placebo-controlled, parallel-group Lauriet clinical trial which assessed the safety and efficacy of semorinemab in mild-to-moderate AD.